Exact Sciences to be Acquired by Abbott Laboratories for $105.00 Per Share in All-Cash Deal
EXAS has more than doubled off its 52-week low of $38.812.
Summary
Exact Sciences Corporation is set to be acquired by Abbott Laboratories for $105.00 per share in cash, a transaction unanimously recommended by Exact Sciences' Board of Directors.
Key Events · M&A and Partnerships · EXAS
-
Acquisition Agreement
Exact Sciences Corporation entered into a definitive merger agreement to be acquired by Abbott Laboratories.
-
Per Share Consideration
Shareholders will receive $105.00 in cash for each share of common stock.
-
Significant Premium
The offer represents a premium of approximately 51% over the unaffected closing share price on November 18, 2025, and 77% over the 60-day volume-weighted average price.
-
Board Recommendation
Exact Sciences' Board of Directors unanimously recommends that stockholders vote to adopt the merger agreement.
Analysis · EXAS · Industrial Applications And Services
This DEFM14A filing announces a definitive agreement for Abbott Laboratories to acquire Exact Sciences Corporation for $105.00 per share in an all-cash transaction. This represents a substantial premium to Exact Sciences' recent trading prices, including a 51% premium over the unaffected closing price on November 18, 2025, and a 77% premium over the 60-day volume-weighted average price. The offer price of $105.00 is also above the current stock price of $101.78 and the 52-week high of $102.66, indicating a favorable exit for shareholders. The Board of Directors has unanimously recommended the merger, highlighting the certainty of value and liquidity for stockholders while eliminating long-term business and execution risks. The acquisition by a global healthcare leader like Abbott provides a strong strategic rationale, potentially accelerating the growth and adoption of Exact Sciences' innovative offerings. The transaction is not subject to a financing condition, reducing execution risk. Shareholders will vote on the merger on February 20, 2026, with the deal expected to close before the end of Q2 2026.
At the time of this filing, EXAS was trading at $101.78 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $19.3B. The 52-week trading range was $38.81 to $102.66. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.